BIOMEDICAL DATA SOLUTIONS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -13.3%

  £7,754,623 → £6,720,991

• Cash

  +5.6%

  £1,311,918 → £1,385,380

• Net assets

  -1.4%

  £4,220,862 → £4,160,723

• Employees

  +4.2%

  72 → 75

• Operating profit

  -94.4%

  £717,180 → £40,089

• Profit before tax

  -95.3%

  £714,644 → £33,463

• Wages

  +8.4%

  £3,982,445 → £4,315,474

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. BIOMEDICAL DATA SOLUTIONS LIMITED 2020-05-05 → present
2. STRATEC BIOMEDICAL UK LIMITED 2011-03-14 → 2020-05-05
3. SANGUIN INTERNATIONAL LIMITED 1988-08-31 → 2011-03-14

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Forvis Mazars LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“As at the balance sheet date, the company has net assets of £4,160,723 and cash of £1,385,380. The Directors have prepared a going concern assessment based upon post year end and forecast trading for the company. The directors have performed sensitivity analysis on these forecasts and concluded the company is able to meet its obligations as they fall due, for at least 12 months from signing these financial statements. The company has done modelling of revenues by project, including levels of new customer acquisition, recurring subscription revenue and churn rates. Detailed modelling has been performed on the level of costs and investments required, taking account of inflation and other macroeconomic trends. The conversion of trading into cash was also modelled, taking account of project timings, liability repayments and potential taxation liabilities. On this basis, the directors are satisfied it is appropriate to prepare these financial statements on a going concern basis.”

Group structure

1. BIOMEDICAL DATA SOLUTIONS LIMITED · parent
   1. Sanguin International Inc. 100% · United States of America · Software systems supplier

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.